Allen Investment Management’s United Therapeutics UTHR Stock Holding History

Allen Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,923	Closed	-$472K	–	187
2019 Q3	$472K	Hold	5,923	–	–	0.01%	137
2019 Q2	$462K	Hold	5,923	–	–	0.01%	144
2019 Q1	$695K	Buy	+5,923	New	+$690K	0.02%	120
2018 Q4	–	Sell	-6,434	Closed	-$823K	–	181
2018 Q3	$823K	Hold	6,434	–	–	0.03%	121
2018 Q2	$728K	Hold	6,434	–	–	0.03%	119
2018 Q1	$723K	Hold	6,434	–	–	0.03%	112
2017 Q4	$952K	Hold	6,434	–	–	0.04%	97
2017 Q3	$754K	Hold	6,434	–	–	0.03%	123
2017 Q2	$835K	Buy	6,434 +2,566	+66%	+$320K	0.04%	115
2017 Q1	$524K	Hold	3,868	–	–	0.03%	145
2016 Q4	$555K	Hold	3,868	–	–	0.03%	135
2016 Q3	$457K	Hold	3,868	–	–	0.03%	136
2016 Q2	$410K	Hold	3,868	–	–	0.03%	150
2016 Q1	$431K	Hold	3,868	–	–	0.03%	142
2015 Q4	$606K	Hold	3,868	–	–	0.05%	110
2015 Q3	$508K	Buy	3,868 +971	+34%	+$156K	0.05%	137
2015 Q2	$504K	Hold	2,897	–	–	0.05%	142
2015 Q1	$500K	Hold	2,897	–	–	0.04%	149
2014 Q4	$375K	Buy	+2,897	New	+$373K	0.03%	167

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Allen Investment Management's UTHR Position: Q4 2019 in Review

Allen Investment Management sold out of United Therapeutics (UTHR) in Q4 2019, closing a stake of 5,923 shares — an estimated $472K sold.

Allen Investment Management first reported a position in UTHR in Q4 2014 and held it in 19 quarters. The position peaked at $952K in Q4 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q4 2019.

Allen Investment Management reported no remaining United Therapeutics position as of Q4 2019 after selling out during the quarter.
Allen Investment Management sold 5,923 United Therapeutics shares in Q4 2019, an estimated $472K.
Allen Investment Management first reported a position in United Therapeutics in Q4 2014 and held it in 19 quarters.
Allen Investment Management's United Therapeutics position peaked at $952K in Q4 2017.
320 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2019.

Based on Allen Investment Management's 13F filing for Q4 2019, filed 4 Feb 2020.